Co-Authors
This is a "connection" page, showing publications co-authored by Luca Quartuccio and Salvatore De Vita.
Connection Strength
5.917
-
Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis. Rheumatology (Oxford). 2021 07 01; 60(7):3476-3477.
Score: 0.954
-
Rev Rhum Ed Fr. 2021 Oct; 88(5):377-381.
Score: 0.945
-
Answer to Vieira et al. "Cytokine profile as a prognostic tool in coronavirus disease 2019". Joint Bone Spine 2020. Doi:10.1016/j.jbspin.2020.09.006. Joint Bone Spine. 2021 01; 88(1):105076.
Score: 0.903
-
Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6. J Med Virol. 2020 11; 92(11):2852-2856.
Score: 0.894
-
Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine. 2020 10; 87(5):439-443.
Score: 0.883
-
Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine. 2020 05; 87(3):191-193.
Score: 0.880
-
Psychological Effects of Lockdown Measures for the COVID-19 Outbreak in Patients with Systemic Lupus Erythematosus. J Multidiscip Healthc. 2021; 14:1475-1488.
Score: 0.238
-
Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. J Clin Virol. 2020 08; 129:104444.
Score: 0.221